ImCheck publishes comprehensive overview of the development results of its first-in-class cancer immunotherapeutic targeting BTN3A to activate Vγ9Vδ2 T cells in Science Translational Medicine
Marseille, France, October 20, 2021 – ImCheck Therapeutics announced today the publication of the preclinical to clinical development of its ...